Changes to This Summary (12/05/2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Revised text to state that the effects observed for tamoxifen and raloxifene show persistence several years after discontinuing active treatment, with longer duration of effect noted for tamoxifen than for raloxifene (cited Cuzick et al. as reference 2).
Added text to state that all fractures were reduced with decreases primarily noted for raloxifene but not for tamoxifen; reduction in vertebral fractures and small reduction in nonvertebral fractures were noted.
Added text to state that a meta-analysis showed an overall 38% risk reduction for selective estrogen receptor modulators in breast cancer incidence; with 5 years of treatment, 42 women would need to be treated to prevent one breast cancer in the first 10 years of follow-up.
Revised text to state that based on solid evidence, tamoxifen treatment increases the risk of endometrial cancer, which was apparent in the first 5 years of follow-up but not beyond; thrombotic vascular events (pulmonary embolism, stroke, deep venous thrombosis); and cataracts.
Revised text to state that a meta-analysis showed that the hazard ratio (HR) for endometrial cancer was 2.18 for tamoxifen and was 1.09 for raloxifene; overall, the HR for venous thromboembolic events was 1.73.
This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.